ArticleTherapeutic advances in medical oncology2026
Risk stratification of in-hospital venous thromboembolism for urological cancers: a multicenter retrospective study.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The current predictive models for venous thromboembolism (VTE) have limitations in predicting VTE risk in patients with urological cancer. Objectives: To establish and validate a risk stratification model for in-hospital VTE in patients with urological cancer. Design: Retrospective, multicenter study. Methods: The clinical data of 735 patients with urological cancer in the Department of Urology at four hospitals in China between January 2019 and December 2024 were analyzed. VTE ( Results: In this study, we developed a risk stratification model using a logistic regression based on variables selected by LASSO and constructed a nomogram to visualize the model. The areas under the receiver operating characteristic curve for the training, validation, and external validation cohorts were 0.933 (95% confidence interval (CI): 0.909-0.957), 0.900 (95% CI: 0.850-0.950), and 0.857 (95% CI: 0.776-0.938), respectively. The corresponding Brier scores for them were 0.070, 0.089, and 0.200. The calibration curve indicated good model performance. Decision curve analysis evaluated the clinical utility of the model and showed that it provided a higher net benefit than the "treat-all" and "treat-none" strategies across a wide range of threshold probabilities, supporting its potential clinical usefulness. Conclusion: A predictive model was developed to estimate the risk of in-hospital VTE in patients with urological cancer, enabling personalized assessment and guiding preventive strategies. Further studies are needed to better validate our model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.